The Comparative Pharmacology and Up-Regulation of Rat Neuronal Nicotinic Receptor Subtype Binding Sites Stably Expressed in Transfected Mammalian Cells

We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2, α3, or α4 subunits in combination with the β2 or β4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat ne...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pharmacology and experimental therapeutics Vol. 310; no. 1; pp. 98 - 107
Main Authors Xiao, Yingxian, Kellar, Kenneth J
Format Journal Article
LanguageEnglish
Published United States American Society for Pharmacology and Experimental Therapeutics 01.07.2004
Subjects
Online AccessGet full text

Cover

Loading…
Abstract We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2, α3, or α4 subunits in combination with the β2 or β4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KXα2β2, KXα2β4, KXα3β2, KXα3β4, KXα4β2, and KXα4β4. The K d values of [ 3 H](±)epibatidine ([ 3 H]EB) binding to membranes from these six cell lines ranged from ∼0.02 to 0.3 nM. The pharmacological profiles of the agonist binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands, including 10 agonists and two antagonists, competed against [ 3 H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the β2 subunit compared with those containing the β4 subunit. An excellent correlation ( r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXα4β2 cells and from rat forebrain tissue, in which [ 3 H]EB binding represents predominantly α4β2 nAChRs. More important, the affinities ( K i values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds.
AbstractList We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor alpha2, alpha3, or alpha4 subunits in combination with the beta2 or beta4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KXalpha2beta2, KXalpha2beta4, KXalpha3beta2, KXalpha3beta4, KXalpha4beta2, and KXalpha4beta4. The Kd values of [3H](+/-)epibatidine ([3H]EB) binding to membranes from these six cell lines ranged from approximately 0.02 to 0.3 nM. The pharmacological profiles of the agonist binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands, including 10 agonists and two antagonists, competed against [3H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the beta2 subunit compared with those containing the beta4 subunit. An excellent correlation (r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXalpha4beta2 cells and from rat forebrain tissue, in which [3H]EB binding represents predominantly alpha4beta2 nAChRs. More important, the affinities (Ki values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds.
We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2, α3, or α4 subunits in combination with the β2 or β4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KXα2β2, KXα2β4, KXα3β2, KXα3β4, KXα4β2, and KXα4β4. The K d values of [ 3 H](±)epibatidine ([ 3 H]EB) binding to membranes from these six cell lines ranged from ∼0.02 to 0.3 nM. The pharmacological profiles of the agonist binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands, including 10 agonists and two antagonists, competed against [ 3 H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the β2 subunit compared with those containing the β4 subunit. An excellent correlation ( r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXα4β2 cells and from rat forebrain tissue, in which [ 3 H]EB binding represents predominantly α4β2 nAChRs. More important, the affinities ( K i values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds.
We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor alpha2, alpha3, or alpha4 subunits in combination with the beta2 or beta4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KXalpha2beta2, KXalpha2beta4, KXalpha3beta2, KXalpha3beta4, KXalpha4beta2, and KXalpha4beta4. The Kd values of [3H](+/-)epibatidine ([3H]EB) binding to membranes from these six cell lines ranged from approximately 0.02 to 0.3 nM. The pharmacological profiles of the agonist binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands, including 10 agonists and two antagonists, competed against [3H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the beta2 subunit compared with those containing the beta4 subunit. An excellent correlation (r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXalpha4beta2 cells and from rat forebrain tissue, in which [3H]EB binding represents predominantly alpha4beta2 nAChRs. More important, the affinities (Ki values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds.
Author Yingxian Xiao
Kenneth J. Kellar
Author_xml – sequence: 1
  givenname: Yingxian
  surname: Xiao
  fullname: Xiao, Yingxian
  organization: Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20057-2195, USA
– sequence: 2
  givenname: Kenneth J
  surname: Kellar
  fullname: Kellar, Kenneth J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15016836$$D View this record in MEDLINE/PubMed
BookMark eNpNkc2P0zAQxS20iO0unLkhX-CWrj8SNzlCtXxIy4La7tmaOOPWq8QOtgP0L-HfJVVXgtPoaX7zNHrvilz44JGQ15wtORflzeOIeclZuWRKrerVM7LgleAF40xekAVjQhSyUtUluUrpkTFelkq-IJe8YlzVUi3In90B6ToMI0TI7ifS7weIA5jQh_2Rgu_ow1hscD_18zp4GizdQKb3OMXgoaf3zoTsvDN0gwbHHCLdTm0-jkg_ON85v6dblzHRbYa2P9Lb32PElLCjztNdBJ8smjzLrzAM0DvwdI19n16S5xb6hK-e5jV5-Hi7W38u7r59-rJ-f1cYWTe5sC2uGm5Y2a1KBa2sVSOYbCowsjFga9k2Spi6sa0VIKzBjileI7TczlDZyWvy7uw7xvBjwpT14JKZPwCPYUpaKVUJUTUzeHMGTQwpRbR6jG6AeNSc6VMX-tTFLEp97mK-ePNkPbUDdv_4p_Bn4O0ZOLj94ZeLqMf_wtfyZKybWv4FNb-Xug
CitedBy_id crossref_primary_10_1124_jpet_107_121228
crossref_primary_10_1021_jm1006148
crossref_primary_10_1016_j_ejmech_2014_04_044
crossref_primary_10_1007_s11064_015_1705_z
crossref_primary_10_1016_j_ejphar_2014_06_005
crossref_primary_10_1124_mol_105_012369
crossref_primary_10_1016_j_bmcl_2005_06_039
crossref_primary_10_1124_mol_115_098285
crossref_primary_10_1186_s12576_024_00913_8
crossref_primary_10_1369_00221554231203038
crossref_primary_10_1002_jlcr_2923
crossref_primary_10_1016_j_aca_2005_09_020
crossref_primary_10_1002_syn_20480
crossref_primary_10_1038_npp_2013_105
crossref_primary_10_1002_cmdc_200700073
crossref_primary_10_1002_cne_24320
crossref_primary_10_1038_s41598_018_24166_9
crossref_primary_10_1016_j_ijbiomac_2014_06_058
crossref_primary_10_1124_mol_106_027458
crossref_primary_10_1124_jpet_118_248070
crossref_primary_10_1002_syn_20776
crossref_primary_10_3389_fnana_2018_00001
crossref_primary_10_1038_npp_2011_322
crossref_primary_10_1007_s43440_022_00375_y
crossref_primary_10_1016_j_bbamem_2014_11_003
crossref_primary_10_1186_2050_6511_14_2
crossref_primary_10_1016_j_neuropharm_2015_02_005
crossref_primary_10_1074_jbc_M111_289546
crossref_primary_10_1074_jbc_M110_105346
crossref_primary_10_1124_jpet_112_192542
crossref_primary_10_1523_JNEUROSCI_1795_17_2017
crossref_primary_10_3390_molecules26123603
crossref_primary_10_3987_COM_08_S_D_19
crossref_primary_10_1124_jpet_110_178236
crossref_primary_10_1111_j_1742_4658_2007_05935_x
crossref_primary_10_1074_jbc_M110_171645
crossref_primary_10_1124_jpet_112_198085
crossref_primary_10_1016_j_bmc_2009_05_021
crossref_primary_10_1016_j_neuropharm_2013_09_023
crossref_primary_10_1016_j_jphysparis_2005_12_012
crossref_primary_10_1021_jm4000374
crossref_primary_10_1016_j_nlm_2012_04_003
crossref_primary_10_1124_mol_106_025338
crossref_primary_10_1021_np900727e
crossref_primary_10_1097_FJC_0000000000000221
crossref_primary_10_1021_acschemneuro_2c00610
crossref_primary_10_1371_journal_pone_0048665
crossref_primary_10_1021_jm500183r
crossref_primary_10_1007_s12192_023_01395_0
crossref_primary_10_1111_j_1471_4159_2007_05011_x
crossref_primary_10_1124_mol_105_012419
crossref_primary_10_1111_j_1471_4159_2009_06299_x
crossref_primary_10_1016_j_neuropharm_2016_07_020
crossref_primary_10_1016_j_bcp_2007_07_039
crossref_primary_10_1016_j_bmcl_2014_04_036
crossref_primary_10_1093_ntr_nty134
crossref_primary_10_1248_yakushi_130_377
crossref_primary_10_1111_j_1471_4159_2011_07408_x
crossref_primary_10_1212_WNL_0000000000001471
crossref_primary_10_1124_mol_105_014902
crossref_primary_10_1016_j_pnpbp_2010_07_037
crossref_primary_10_1523_JNEUROSCI_2112_05_2005
crossref_primary_10_1124_mol_116_106880
crossref_primary_10_1113_JP274467
crossref_primary_10_1096_fj_10_179853
crossref_primary_10_1007_s00213_012_2808_8
crossref_primary_10_1021_jm900225j
crossref_primary_10_1124_mol_115_099978
crossref_primary_10_1038_mp_2009_59
crossref_primary_10_1002_med_20036
crossref_primary_10_1101_cshperspect_a039776
crossref_primary_10_2967_jnumed_111_092338
crossref_primary_10_1186_2046_1682_4_19
crossref_primary_10_1007_s10571_007_9149_x
crossref_primary_10_1016_j_ejmech_2015_03_025
crossref_primary_10_1016_j_lfs_2012_08_004
crossref_primary_10_1371_journal_pone_0143319
crossref_primary_10_1124_jpet_113_211235
crossref_primary_10_1016_j_bbamem_2009_06_012
crossref_primary_10_1016_j_bcp_2009_05_024
crossref_primary_10_1002_syn_22116
crossref_primary_10_4049_jimmunol_179_5_2889
crossref_primary_10_1021_jm401543h
crossref_primary_10_1111_j_1471_4159_2008_05282_x
crossref_primary_10_1111_j_1471_4159_2010_06967_x
crossref_primary_10_1016_j_bcp_2015_07_030
crossref_primary_10_1074_jbc_M806136200
crossref_primary_10_1002_syn_20693
crossref_primary_10_1002_bip_22413
crossref_primary_10_1007_s00213_018_4883_y
crossref_primary_10_1038_mp_2013_104
crossref_primary_10_1002_psc_2467
crossref_primary_10_1111_j_1471_4159_2010_06819_x
crossref_primary_10_1124_mol_106_027326
crossref_primary_10_1016_j_neulet_2023_137279
crossref_primary_10_1016_j_nucmedbio_2014_12_008
crossref_primary_10_1124_mol_104_002345
crossref_primary_10_1016_j_bcp_2013_06_023
crossref_primary_10_1124_mol_105_021782
crossref_primary_10_1021_acs_jnatprod_8b00062
crossref_primary_10_1016_j_neuropharm_2007_05_026
crossref_primary_10_1111_j_1601_183X_2008_00444_x
crossref_primary_10_1021_jm4008455
crossref_primary_10_1111_j_1471_4159_2007_05009_x
crossref_primary_10_1016_j_neuropharm_2007_05_021
crossref_primary_10_1074_jbc_M109_019083
crossref_primary_10_1208_aapsj070486
crossref_primary_10_1038_aps_2009_68
crossref_primary_10_1016_j_bmcl_2012_02_052
crossref_primary_10_1124_jpet_110_173773
crossref_primary_10_1074_jbc_M110_108803
crossref_primary_10_1124_mol_106_027318
crossref_primary_10_1038_aps_2009_69
crossref_primary_10_1021_jm401184f
crossref_primary_10_1016_j_neuropharm_2016_06_032
crossref_primary_10_1074_jbc_M707330200
crossref_primary_10_1021_jm800323d
crossref_primary_10_1124_mol_118_114769
crossref_primary_10_1371_journal_pone_0254247
crossref_primary_10_2967_jnumed_108_061374
crossref_primary_10_1007_s00259_007_0701_1
crossref_primary_10_1152_physrev_00015_2008
crossref_primary_10_1007_s00213_016_4238_5
crossref_primary_10_1016_j_jneuroim_2005_05_007
Cites_doi 10.1016/0006-2952(73)90196-2
10.1124/mol.51.5.776
10.1523/JNEUROSCI.18-13-04946.1998
10.1016/0006-8993(93)91104-Z
10.1016/0169-328X(94)00189-L
10.1111/j.1469-7793.1997.299bb.x
10.1124/mol.55.6.970
10.1111/j.1471-4159.1988.tb10600.x
10.1016/0014-5793(90)81231-C
10.1523/JNEUROSCI.12-07-02765.1992
10.1074/jbc.270.9.4424
10.1126/science.6828889
10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X
10.1124/mol.54.5.779
10.1074/jbc.273.44.28721
10.1124/mol.64.6.1283
10.1111/1523-1747.ep12325606
10.1073/pnas.84.21.7763
10.1016/S0079-6123(08)62094-4
10.1016/S1054-3589(08)60072-1
10.1046/j.1471-4159.1996.67051953.x
10.1016/S0079-6123(08)62480-2
10.1152/jn.1995.74.3.1212
10.1124/mol.54.6.1132
10.1016/S0028-3908(98)00221-4
10.1046/j.1471-4159.1997.69052216.x
10.1124/mol.54.2.322
10.1046/j.1471-4159.2003.01774.x
10.1124/mol.64.4.974
10.1073/pnas.84.2.595
10.1016/0896-6273(89)90207-9
10.1046/j.1471-4159.2002.00951.x
10.1113/jphysiol.2001.013456
10.1073/pnas.0630641100
10.1124/mol.64.4.865
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1124/jpet.104.066787
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0103
EndPage 107
ExternalDocumentID 10_1124_jpet_104_066787
15016836
310_1_98
Genre Research Support, U.S. Gov't, P.H.S
Journal Article
Comparative Study
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: DA06486
– fundername: NIDA NIH HHS
  grantid: DA12976
GroupedDBID -
08R
0R
2WC
3O-
4.4
53G
55
5GY
5RE
8RP
AALRV
ABFLS
ABIVO
ABOCM
ABSGY
ABZEH
ACDCL
ACGFS
ACNCT
ADACO
ADBIT
ADCOW
ADKFC
AENEX
AETEA
AFFNX
AIKQT
ALMA_UNASSIGNED_HOLDINGS
CS3
DIK
DL
DU5
E3Z
EBS
EJD
F5P
FH7
GJ
GX1
H13
HZ
INIJC
KQ8
L7B
LSO
O0-
O9-
OHT
OK1
P2P
R.V
R0Z
RHF
RHI
RPT
W2D
WH7
WOQ
X
X7M
ZGI
ZXP
---
-~X
.55
.GJ
0R~
18M
5VS
8WZ
A6W
AAJMC
AAYOK
ABCQX
ABJNI
ABSQV
ACGFO
ADBBV
ADIYS
AERNN
AFHIN
AFOSN
AGFXO
AI.
BAWUL
BTFSW
CGR
CUY
CVF
ECM
EIF
F9R
HZ~
MJL
MVM
NPM
TR2
UQL
VH1
W8F
YBU
YHG
YQT
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c389t-fbe791c04d746ab386920395ac39caf83b962c89fbf2a2fced0618eab1f95a4d3
ISSN 0022-3565
IngestDate Fri Oct 25 05:31:16 EDT 2024
Thu Sep 26 17:48:18 EDT 2024
Sat Sep 28 07:41:56 EDT 2024
Tue Jan 05 21:16:48 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c389t-fbe791c04d746ab386920395ac39caf83b962c89fbf2a2fced0618eab1f95a4d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 15016836
PQID 66652259
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_66652259
crossref_primary_10_1124_jpet_104_066787
pubmed_primary_15016836
highwire_pharmacology_310_1_98
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 2004-07-01
PublicationDateYYYYMMDD 2004-07-01
PublicationDate_xml – month: 07
  year: 2004
  text: 2004-07-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of pharmacology and experimental therapeutics
PublicationTitleAlternate J Pharmacol Exp Ther
PublicationYear 2004
Publisher American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: American Society for Pharmacology and Experimental Therapeutics
References 2019081412044966000_310.1.98.4
2019081412044966000_310.1.98.5
2019081412044966000_310.1.98.7
2019081412044966000_310.1.98.8
2019081412044966000_310.1.98.9
2019081412044966000_310.1.98.32
2019081412044966000_310.1.98.30
2019081412044966000_310.1.98.2
2019081412044966000_310.1.98.34
2019081412044966000_310.1.98.3
2019081412044966000_310.1.98.39
(2019081412044966000_310.1.98.46) 1995; 28
2019081412044966000_310.1.98.38
2019081412044966000_310.1.98.37
(2019081412044966000_310.1.98.29) 1998; 285
(2019081412044966000_310.1.98.22) 1989; 79
(2019081412044966000_310.1.98.48) 1998; 18
2019081412044966000_310.1.98.43
(2019081412044966000_310.1.98.17) 1996; 276
2019081412044966000_310.1.98.42
(2019081412044966000_310.1.98.19) 1996; 67
2019081412044966000_310.1.98.41
2019081412044966000_310.1.98.47
(2019081412044966000_310.1.98.15) 1997; 69
2019081412044966000_310.1.98.44
(2019081412044966000_310.1.98.28) 1992; 12
2019081412044966000_310.1.98.49
(2019081412044966000_310.1.98.16) 1992; 41
(2019081412044966000_310.1.98.45) 1991; 40
(2019081412044966000_310.1.98.31) 2001; 60
2019081412044966000_310.1.98.10
(2019081412044966000_310.1.98.36) 1999; 289
2019081412044966000_310.1.98.14
2019081412044966000_310.1.98.13
(2019081412044966000_310.1.98.40) 1998; 284
2019081412044966000_310.1.98.12
2019081412044966000_310.1.98.11
2019081412044966000_310.1.98.18
(2019081412044966000_310.1.98.1) 1997; 280
(2019081412044966000_310.1.98.35) 1994; 46
(2019081412044966000_310.1.98.20) 1999; 25
(2019081412044966000_310.1.98.25) 1998; 287
(2019081412044966000_310.1.98.26) 1995; 74
(2019081412044966000_310.1.98.33) 1996; 278
(2019081412044966000_310.1.98.27) 1983; 226
2019081412044966000_310.1.98.21
2019081412044966000_310.1.98.24
2019081412044966000_310.1.98.23
(2019081412044966000_310.1.98.6) 1997; 280
References_xml – volume: 25
  start-page: 980
  year: 1999
  ident: 2019081412044966000_310.1.98.20
  publication-title: Soc Neurosci
– ident: 2019081412044966000_310.1.98.7
  doi: 10.1016/0006-2952(73)90196-2
– ident: 2019081412044966000_310.1.98.34
  doi: 10.1124/mol.51.5.776
– volume: 18
  start-page: 4946
  year: 1998
  ident: 2019081412044966000_310.1.98.48
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.18-13-04946.1998
– ident: 2019081412044966000_310.1.98.38
  doi: 10.1016/0006-8993(93)91104-Z
– volume: 28
  start-page: 101
  year: 1995
  ident: 2019081412044966000_310.1.98.46
  publication-title: Brain Res Mol Brain Res
  doi: 10.1016/0169-328X(94)00189-L
– volume: 289
  start-page: 1545
  year: 1999
  ident: 2019081412044966000_310.1.98.36
  publication-title: J Pharmacol Exp Ther
– ident: 2019081412044966000_310.1.98.23
  doi: 10.1111/j.1469-7793.1997.299bb.x
– ident: 2019081412044966000_310.1.98.49
  doi: 10.1124/mol.55.6.970
– ident: 2019081412044966000_310.1.98.3
  doi: 10.1111/j.1471-4159.1988.tb10600.x
– ident: 2019081412044966000_310.1.98.43
  doi: 10.1016/0014-5793(90)81231-C
– volume: 12
  start-page: 2765
  year: 1992
  ident: 2019081412044966000_310.1.98.28
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.12-07-02765.1992
– volume: 60
  start-page: 568
  year: 2001
  ident: 2019081412044966000_310.1.98.31
  publication-title: Mol Pharmacol
– ident: 2019081412044966000_310.1.98.9
  doi: 10.1074/jbc.270.9.4424
– ident: 2019081412044966000_310.1.98.39
  doi: 10.1126/science.6828889
– volume: 46
  start-page: 523
  year: 1994
  ident: 2019081412044966000_310.1.98.35
  publication-title: Mol Pharmacol
– ident: 2019081412044966000_310.1.98.5
  doi: 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X
– ident: 2019081412044966000_310.1.98.30
  doi: 10.1124/mol.54.5.779
– ident: 2019081412044966000_310.1.98.41
  doi: 10.1074/jbc.273.44.28721
– ident: 2019081412044966000_310.1.98.13
  doi: 10.1124/mol.64.6.1283
– ident: 2019081412044966000_310.1.98.18
  doi: 10.1111/1523-1747.ep12325606
– ident: 2019081412044966000_310.1.98.4
  doi: 10.1073/pnas.84.21.7763
– volume: 276
  start-page: 289
  year: 1996
  ident: 2019081412044966000_310.1.98.17
  publication-title: J Pharmacol Exp Ther
– ident: 2019081412044966000_310.1.98.24
  doi: 10.1016/S0079-6123(08)62094-4
– ident: 2019081412044966000_310.1.98.8
  doi: 10.1016/S1054-3589(08)60072-1
– volume: 67
  start-page: 1953
  year: 1996
  ident: 2019081412044966000_310.1.98.19
  publication-title: J Neurochem
  doi: 10.1046/j.1471-4159.1996.67051953.x
– volume: 284
  start-page: 777
  year: 1998
  ident: 2019081412044966000_310.1.98.40
  publication-title: J Pharmacol Exp Ther
– volume: 79
  start-page: 209
  year: 1989
  ident: 2019081412044966000_310.1.98.22
  publication-title: Prog Brain Res
  doi: 10.1016/S0079-6123(08)62480-2
– volume: 74
  start-page: 1212
  year: 1995
  ident: 2019081412044966000_310.1.98.26
  publication-title: J Neurophysiol
  doi: 10.1152/jn.1995.74.3.1212
– ident: 2019081412044966000_310.1.98.32
  doi: 10.1124/mol.54.6.1132
– volume: 287
  start-page: 435
  year: 1998
  ident: 2019081412044966000_310.1.98.25
  publication-title: J Pharmacol Exp Ther
– ident: 2019081412044966000_310.1.98.10
  doi: 10.1016/S0028-3908(98)00221-4
– volume: 278
  start-page: 361
  year: 1996
  ident: 2019081412044966000_310.1.98.33
  publication-title: J Pharmacol Exp Ther
– volume: 41
  start-page: 31
  year: 1992
  ident: 2019081412044966000_310.1.98.16
  publication-title: Mol Pharmacol
– volume: 69
  start-page: 2216
  year: 1997
  ident: 2019081412044966000_310.1.98.15
  publication-title: J Neurochem
  doi: 10.1046/j.1471-4159.1997.69052216.x
– volume: 280
  start-page: 346
  year: 1997
  ident: 2019081412044966000_310.1.98.6
  publication-title: J Pharmacol Exp Ther
– ident: 2019081412044966000_310.1.98.47
  doi: 10.1124/mol.54.2.322
– ident: 2019081412044966000_310.1.98.11
  doi: 10.1046/j.1471-4159.2003.01774.x
– volume: 40
  start-page: 463
  year: 1991
  ident: 2019081412044966000_310.1.98.45
  publication-title: Mol Pharmacol
– ident: 2019081412044966000_310.1.98.2
  doi: 10.1124/mol.64.4.974
– ident: 2019081412044966000_310.1.98.44
  doi: 10.1073/pnas.84.2.595
– ident: 2019081412044966000_310.1.98.12
  doi: 10.1016/0896-6273(89)90207-9
– volume: 285
  start-page: 377
  year: 1998
  ident: 2019081412044966000_310.1.98.29
  publication-title: J Pharmacol Exp Ther
– ident: 2019081412044966000_310.1.98.37
  doi: 10.1046/j.1471-4159.2002.00951.x
– volume: 226
  start-page: 817
  year: 1983
  ident: 2019081412044966000_310.1.98.27
  publication-title: J Pharmacol Exp Ther
– ident: 2019081412044966000_310.1.98.42
  doi: 10.1113/jphysiol.2001.013456
– ident: 2019081412044966000_310.1.98.14
  doi: 10.1073/pnas.0630641100
– ident: 2019081412044966000_310.1.98.21
  doi: 10.1124/mol.64.4.865
– volume: 280
  start-page: 1117
  year: 1997
  ident: 2019081412044966000_310.1.98.1
  publication-title: J Pharmacol Exp Ther
SSID ssj0014463
Score 2.2282128
Snippet We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2, α3, or α4 subunits in combination...
We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor alpha2, alpha3, or alpha4 subunits in...
SourceID proquest
crossref
pubmed
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 98
SubjectTerms Animals
Binding Sites
Bridged Bicyclo Compounds, Heterocyclic - pharmacology
Carbachol - pharmacology
Cell Line
Cholinergic Agonists - pharmacology
Gene Expression - drug effects
Humans
Neurons - drug effects
Neurons - metabolism
Nicotine - pharmacology
Nicotinic Agonists - pharmacology
Pyridines - pharmacology
Rats
Receptors, Nicotinic - drug effects
Receptors, Nicotinic - metabolism
Transfection
Tritium
Up-Regulation - drug effects
Title The Comparative Pharmacology and Up-Regulation of Rat Neuronal Nicotinic Receptor Subtype Binding Sites Stably Expressed in Transfected Mammalian Cells
URI http://jpet.aspetjournals.org/content/310/1/98.abstract
https://www.ncbi.nlm.nih.gov/pubmed/15016836
https://search.proquest.com/docview/66652259
Volume 310
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadchh_QhNSlpHGS2o9QDU2bQDBaqTxFdmKLSr1pSyXGH-HfIs6xk9Tphri8RG1SOW6-L8ffsc85JuTlkHElTJ4EYaiiABRxHshEDoJhUXClQqU1x0Th9x_S40l8Mk2mnc5PL2ppU6p-_v3avJL_QRXOAa6YJfsPyDaNwgn4DPjCERCG419jPPLKd3_c1qF2ZZUm6-DMbTZf6cIzWfZsPQ4UociCEhMjUTzqNXjfaEfspOzbmct2-TzDeVlQpGp-iWWRbalxLNfkqqJjLIjGQI3Fws2XjPR8fuEL3m3qmRW9690etnYY8JLBGqn_BbrxDZuezuSqNTyUX3sn_d4phm-dtyYv4ibQtfTyBdCQeSGqV57Vkd-T8W5P_KQEt-1EX1e2PMKZkpD5xp5VQbQ-q53pdpthXx1RohhHFHBhcDm8jzHBTiF4_FovLMFAWw9Szq6p7L0z4jZxkAxdsEzwG-RmBIYSLfTpp-0qGLjqrKl2D3-uKk0FXXq90yG7u5S7e1tg1UWvf-9AWSE1vkNuV2Sgbxyd75KOXt4jBxUcl4fUf_SH9ID6QN0nP-Ay9TjfukwBR9riPF0ZCpynNedpw3lac55WnKcV56nlPHWcpw3n6WxJPc7ThvPUcv4Bmbw7Go-Og2pzkSAHjV4GRumhGORhXAzjVCrGUxGFTCQyZyKXhjMl0ijnwigTycjkugDly7VUAwM_igv2kOwtV0v9mFApBiZkMkwVl-DNpzwXOgEhbGLJRcRNl7yqEcnWroZMZn3vKM4QR_gSZw7HLtmvEcv8NzKrmdIlL2ocMxgIcHVPLvVqc5GlaQq-VCK65JGDd3uvihlP_tT4U3Jr-5I-I3vl-UY_B81dqn1LzF8Or-MJ
link.rule.ids 315,783,787,27936,27937
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Comparative+Pharmacology+and+Up-Regulation+of+Rat+Neuronal+Nicotinic+Receptor+Subtype+Binding+Sites+Stably+Expressed+in+Transfected+Mammalian+Cells&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Yingxian+Xiao&rft.au=Kenneth+J.+Kellar&rft.date=2004-07-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0022-3565&rft.eissn=1521-0103&rft.volume=310&rft.issue=1&rft.spage=98&rft_id=info:doi/10.1124%2Fjpet.104.066787&rft_id=info%3Apmid%2F15016836&rft.externalDBID=n%2Fa&rft.externalDocID=310_1_98
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon